There is an increasing role for immunotherapy in the treatment of superficial recurrent bladder tumors and carcinoma in situ. BCG has proved to be an effective means of intravesical immunotherapy and a considerable experience with the treatment has accumulated. Other agents such as poly I:C, OK432 and transfer factor have not proved to be as effective. Interferon has shown impressive preliminary results but needs further evaluation in larger numbers of patients before definitive conclusions can be drawn.
ASJC Scopus subject areas